How Methandrostenolone (Dianabol) Affects ALT

Methandrostenolone (Dianabol, Dbol) is a 17-alpha-alkylated (C17-aa) oral anabolic steroid. The 17-alpha-alkylation is what makes it orally bioavailable, but this structural modification is also what makes it hepatotoxic:

1. First-pass hepatic metabolism: Oral steroids pass through the liver during absorption. The C17-aa modification resists hepatic breakdown, meaning the liver is exposed to high concentrations of the active compound.
2. Cholestatic stress: C17-aa steroids impair bile flow (cholestasis) by affecting bile salt transport proteins (BSEP and MRP2). This causes bile acids to accumulate in hepatocytes, triggering inflammation and cell damage.
3. Oxidative stress: The hepatic metabolism of Dianabol generates reactive oxygen species (ROS), causing direct oxidative damage to hepatocytes.
4. Hepatocyte membrane disruption: ALT is released when hepatocyte cell membranes are damaged or become more permeable. Even mild hepatocellular injury raises circulating ALT.

Dianabol is considered moderately hepatotoxic among oral steroids. It is less liver-toxic than compounds like superdrol or halotestin but more hepatotoxic than oxandrolone.

Low doses (20-30 mg/day):

• ALT typically rises 1.5-3x the upper limit of normal (ULN)
• Many users see ALT in the 60-120 U/L range (normal: below 40 U/L)
• GGT and bilirubin may also rise mildly

Moderate to high doses (40-60+ mg/day):

• ALT commonly rises 2-5x ULN (80-200+ U/L)
• AST rises in parallel but usually to a lesser degree
• ALP and GGT may indicate cholestatic component
• Bilirubin may elevate, occasionally causing visible jaundice at very high doses

Timeline: ALT elevation begins within the first week and typically peaks at 3-4 weeks. Values are highest during the period of active use and begin declining within 1-2 weeks of discontinuation.

Context: Dianabol is typically used for 4-6 week "kickstart" cycles at the beginning of a longer injectable cycle. This limited duration helps contain liver damage, but repeated short cycles still cause cumulative stress.

Pre-cycle: Obtain baseline liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin) before starting Dianabol. Do not start if ALT is already above normal.

On cycle: Check liver enzymes at week 3-4. This is typically the peak of hepatic stress.

Post-cycle: Recheck liver enzymes 2-4 weeks after discontinuation to confirm recovery.

Warning signs requiring immediate cessation:

• ALT exceeding 5x ULN (above 200 U/L)
• Rising bilirubin (especially direct/conjugated bilirubin)
• Dark urine or pale stools (signs of cholestasis)
• Right upper quadrant pain or tenderness
• Jaundice (yellowing of skin or eyes)
• Unexplained nausea, fatigue, or loss of appetite

Liver support during Dianabol use:

• TUDCA (tauroursodeoxycholic acid) 500-1000 mg/day is the most evidence-based hepatoprotectant for C17-aa steroid use. It supports bile flow and protects against cholestatic injury.
• NAC (N-acetylcysteine) 600-1200 mg/day supports glutathione synthesis and reduces oxidative stress.
• Milk thistle (silymarin) 500-1000 mg/day provides modest hepatoprotective effects.

Cycle design:

• Limit Dianabol use to 4-6 weeks maximum
• Do not stack multiple C17-aa oral steroids simultaneously
• Allow at least 6-8 weeks of recovery between oral steroid cycles
• Use the lowest effective dose; 20-30 mg/day is sufficient for most users

Lifestyle factors:

• Eliminate or minimise alcohol consumption during oral steroid use
• Stay well-hydrated
• Avoid other hepatotoxic medications (acetaminophen/paracetamol, statins) if possible during the cycle
• Maintain a diet supporting liver health: adequate protein, cruciferous vegetables, avoid excessive fructose

If ALT exceeds 5x ULN: Discontinue Dianabol immediately. Continue TUDCA and NAC. Recheck in 2 weeks. If ALT does not begin declining, seek medical evaluation.